Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

"LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis."

http://www.fiercemedicaldevices.com/press-releases/amarantus-bioscience-licenses-lympro-alzheimers-disease-diagnostic-blood-te

If these are in-line with the numbers that Gerald will release this week the share price will hit the .40-.50 range. The global media coverage on LymPro will be tremendous.

.70 by the up-listing.

Stay tuned for news.

"The trend is your friend but it's the science that will make you rich."

Twitter: @AmarantusBio .... 10,000+ followers.


p.s. Expecting new article from Jason Napadano by next Monday. He'll be all over the update.

Note: I think the news is getting out that Gerald has several rabbits in his hat and a few cards up his sleeve.